Boston Scientific updates Polarx catheter guidelines due to atrio-esophageal fistula risks, highlighting safer usage practices after FDA approval.

Boston Scientific Corporation BSX remains in the spotlight, with its stock currently trading close to its 52-week high. In the past six trading sessions, the stock has consistently traded above $90.00 ...

Pulsed field ablation could soon be used in the majority of electrophysiology procedures to treat atrial fibrillation as ...

Citi raised the firm’s price target on Boston Scientific (BSX) to $107 from $98 and keeps a Buy rating on the shares. The firm also added the ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Boston Scientific (BSX – Research Report), with a ...

AFib-treating cardiac ablation, surgical robotics, nitinol and diabetes treatment tech lead among this year’s top medtech ...

Elizabeth Kensinger, professor of psychology and neuroscience at Boston College, asks this same question as ... Apart from memory, Kensinger said she believes the creative aspect of scientific study ...

Boston Scientific (BSX) ended the recent trading session at $90.53, demonstrating a -0.34% swing from the preceding day's closing price. This change lagged the S&P 500's 0.19% loss on the day.

Valued at a market cap of $133.6 billion, Boston Scientific Corporation (BSX ... strategic acquisitions like Farapulse, its category leadership strategy, and robust operational execution ...

presents significant growth opportunities for Boston Scientific's Watchman device. 1. Product Pipeline: The successful launch of new products, such as the U.S. Farapulse PFA, is expected to ...

Valued at a market cap of $133.6 billion, Boston Scientific Corporation (BSX) develops, manufactures, and markets medical ...

The initiative, called the “Greater Boston Coastal Resilience Jobs Alliance,” is one of nine nationally funded by the Inflation Reduction Act, a legislative package passed under the Biden ...